Johannesburg - Aspen Pharmacare [JSE:APN], Africa's biggest drugmaker by value, missed forecasts with an almost one-third rise in full-year profit on Wednesday as a weak African home market offset contributions from recent acquisitions.
Aspen, which supplies to about 150 countries that include Australia, Nigeria, Brazil and the United States, said diluted headline EPS totalled 1 016 cents for the year to the end of June, compared with 787c a year earlier.
That was below the 1 071c estimate in a Reuters poll of 12 analysts.
Aspen, which supplies to about 150 countries that include Australia, Nigeria, Brazil and the United States, said diluted headline EPS totalled 1 016 cents for the year to the end of June, compared with 787c a year earlier.
That was below the 1 071c estimate in a Reuters poll of 12 analysts.